Erik Greb joined the staff of Neurology Reviews in January 2012. Since then, he has attended scientific conferences, conducted video interviews, and written about clinical research in multiple sclerosis, epilepsy, Parkinson's disease, Alzheimer's disease, stroke, and other neurologic disorders. In addition to news articles, Erik has written investigative stories about multiple sclerosis, headache, and epilepsy. He previously wrote about pharmaceutical manufacturing, drug formulation and delivery, quality assurance, and regulation for Pharmaceutical Technology.
News
Progressive disability in MS explained?
Complete resolution of brain lesions may help distinguish MS, MOGAD, and AQP4+ NMOSD.
News
Atogepant reduces migraine days: ADVANCE trial results published
“Overall, this study showed us that atogepant was safe and surprisingly seems to be pretty effective regardless of the dose.”
News
Virtual roller-coaster may explain the ups and downs of migraine
The prevalence of dizziness was 65% among patients with migraine who underwent a virtual roller-coaster ride, versus 30% among those without...
News
Is walking speed following stroke a good predictor of recovery?
Training enabled both “good” and “limited” walkers to increase travel distance during a 2-minute walk.
News
Novel NSAID–triptan drug effectively relieves migraine pain
About 74% of patients who received AXS-07 experienced no progression of pain from 2 to 24 hours.
News
No increased risk of hypertension with erenumab?
The rate of hypertension adverse events in postmarketing data was 0.144 per 100 person-years.
News
A large proportion of migraine patients are not offered preventive treatment
Among patients eligible for preventive therapy, more than a third were not offered this option, fewer than 10% were currently taking preventive...
News
Almost half of patients with migraine are reluctant to seek care
Common reasons for failure to seek treatment included believing that migraine was not severe enough to warrant a consultation, worries about cost...
News
A new biomarker of traumatic brain injury?
“Von Willebrand factor may be more specific for acute injuries, given that it does not seem to stay chronically elevated.”
News
NfL beats T-tau as a prognostic marker of cognitive decline
NfL was cross-sectionally associated with most cognitive outcomes; longitudinally, higher NfL at baseline was associated with cognitive decline in...
News
Investigational drug reduces brain lesions in highly active MS
Tolebrutinib, a BTK inhibitor, reduced new gadolinium-enhancing lesions and new and enlarging T2 lesions.
News
Long-term benefit for DBS in treating Parkinson’s disease motor symptoms
“Both STN and GPi DBS maintained motor benefit out to 10 years, with improvements seen in tremor and rigidity, greater than bradykinesia.”